Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
Medical Oncology
•
Leukemia
•
MD Anderson
•
AML
•
AYA
•
AYA Tumor Board
If AYA patients with AML are MRD negative after 1 cycle of chemotherapy, and high risk for relapse, should they receive additional cycles of chemotherapy or proceed directly to transplant?
Related Questions
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
Is there a concern for the potential of future congenital malformations in offspring when preservation of eggs and sperm is done AFTER cyclophosphamide treatment given that it is an alkylating agent?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
For AML patients, when do you stop antiinfective agents?
How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?
Would you consider a cycle of EP in a patient with good risk stage IIIB seminoma on BEP but with bleomycin omitted for cycle 3?
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?